DCC1697 |
Dc-k2in212 |
Novel potent CDK2 inhibitor with selectivities above 10-fold over CDK1/4/6/7/9/12 above 10-fold, displaying anti-proliferative activity against A2058 melanoma and MV4-11 leukemia cell lines and low toxicity on human normal cell lines, inhibiting CDK2-medi |
|
DCC1698 |
Dcn1-ubc12 Inhibitor Dn-2 |
Novel potent and selective DCN1-UBC12 inhibitor for anticardiac fibrotic effects, specifically targetinbg DCN1 at molecular and cellular levels, effectively reversing angiotensin (Ang) II-induced cardiac fibroblast activation |
|
DCC1699 |
Dc-prc2in-01 |
Novel PRC2 Inhibitor, Targeting EZH2-EED Interaction |
|
DCC1700 |
Dc-s100 |
Novel, Selective Histone Methyltransferase SET7 Inhibitor |
|
DCC1701 |
Dc-s238 |
Novel, Potent and Selective Histone Methyltransferase SET7 Inhibitor |
|
DCC1702 |
Dc-s239 |
Novel, Potent and Selective Histone Methyltransferase SET7 Inhibitor |
|
DCC1703 |
Dc-teadin02 |
Novel potent and selective TEAD autopalmitoylation inhibitor, inhibiting TEADs transcription activity and downstream gene expression |
|
DCC1704 |
Dcz3112 |
Novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction |
|
DCC1705 |
Dd-04-015 |
Novel selective BTK degrader, demonstrating prolonged pharmacodynamic effects |
|
DCC1706 |
Dd04107
Featured
|
Novel inhibitor of α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons, selectively interacting with Synaptotagmin 1 |
|
DCC1707 |
Ddc4002 |
First-generation allosteric EGFR inhibitor, binding to the allosteric site of EGFR along with ATP that leads to inhibition of cell proliferation and arrest of EGFR L858R/T790M/C797S signalling |
|
DCC1708 |
Ddd00015314 |
Novel activator of the GUS reporter activity, specific increasing in stumpy reporter gene expression |
|
DCC1709 |
Ddd01035881 |
Novel transmission blocker of antimalarials, targeting male gametes |
|
DCC1710 |
Ddd-028 |
Potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain |
|
DCC1711 |
Ddd100097 |
Potent inhibitor of Trypanosoma brucei N-myristoyltransferase (TbNMT) with markedly improved blood-brain barrier permeability |
|
DCC1712 |
Ddhctp Sodium Salt |
Novel potent and broad-spectrum antiviral agent, acting as a chain terminator for viral RNA polymerase |
|
DCC1713 |
Ddo-2117 |
Novel potent blocker of mixed lineage leukemia 1 (MLL1)-WDR5 interaction, inhibiting MLL1 complex H3K4 methyltransferase activity |
|
DCC1714 |
Ddo-2213 |
Novel Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 (MLL1) Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia |
|
DCC1715 |
Ddo-7132 |
Novel NQO1 substrate, inhibiting cancer cell (NQO1-rich A549 cell line) growth |
|
DCC1716 |
Ddo-7204 |
Novel Nrf2 activator |
|
DCC1717 |
ddpm-1457 |
Potent mGAT4 inhibitor |
|
DCC1718 |
Ddr1-in-2 |
Potent and selective DDR1 receptor tyrosine kinase inhibitor |
|
DCC1719 |
Ddri-18 |
Inhibitor of nonhomologous end-joining (NHEJ) DNA repair following double strand DNA breaks induced by ionizing radiation, enhancing the effects of DNA-damaging cancer drugs like etoposide, camptothecin and doxorubicin |
|
DCC1720 |
Ddr-trk-1n |
Negative control for DDR-TRK-1 |
|
DCC1721 |
Dea Nonoate Sodium Salt |
NO donor, generating a controlled release of nitric oxide in solution. |
|
DCC1722 |
Deacm-caged D-luciferin |
Coumarin-caged D-luciferin, being excited in the caged group only by light of wavelength ranging within 400-430 nm |
|
DCC1723 |
Deac-pda-atp |
Fluorophore to myosin or actomyosin |
|
DCC1724 |
Debio-1452-nh3 |
Novel potent inhibitor of the enoyl-acyl carrier protein reductase FabI, reducing bacterial burden in mice and rescuing mice from lethal infections with clinical isolates of Acinetobacter baumannii, Klebsiella pneumoniae and E. coli |
|
DCC1725 |
Deferasirox Ferrate(iii) Tripotassium Complex |
Deferasirox iron complex |
|
DCC1726 |
Deferoxamine Hydrochloride |
Iron chelating agent, chelating iron from intra-lysosomal ferritin and hemosiderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile |
|